Skip to main content

Ventas Value Stock - Dividend - Research Selection

Ventas

ISIN: US92276F1003 , WKN: 878380

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Ventas, Inc., an S&P 500 company, is a leading real estate investment trust. Its diverse portfolio of more than 1,200 assets in the United States, Canada and the United Kingdom consists of seniors housing communities, medical office buildings, life science and innovation centers, inpatient rehabilitation and long-term acute care facilities, health systems and skilled nursing facilities. Through its Lillibridge subsidiary, Ventas provides management, leasing, marketing, facility development and advisory services to highly rated hospitals and health systems throughout the United States. References to ?Ventas? or the ?Company? mean Ventas, Inc. and its consolidated subsidiaries unless otherwise expressly noted. More information about Ventas and Lillibridge can be found at www.ventasreit.com and www.lillibridge.com.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


What's in the Offing for Ventas Stock This Earnings Season?

2026-02-02
VTR's Q4 earnings are expected to show solid revenue and FFO growth, driven by SHOP & OM&R portfolio strength despite weakness in triple-net leased properties.

AI Capex Clouds The Tech Horizon, Even As Meta And Tesla Shine

2026-02-02
On Thursday, Nasdaq fell 1.3% as the market digested mixed results from some Mag 7 reports. The primary weight came from Microsoft. AI spending anxiety rippled through the software sector.

January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week

2026-02-01
Crucial labor market data, more earnings from Big Tech giants, and continued discussion over where Kevin Warsh may lead the central bank should set the agenda in the week ahead.

Warshed Out: The Dollar Fights Back

2026-02-01

Duff & Phelps Loads Up on First Industrial Realty Trust With 735K Shares

2026-02-01
This investment firm recently increased its position on one of the top industrial REITs in the nation.

The DGI Core Portfolio: 2025 Year-End Review

2026-01-31

Key Themes To Watch This REIT Earnings Season

2026-01-30
REIT earnings season is here: outlook on rates, housing, senior living, office, retail, and risks in hotels, logistics & data centers.

The Polar Pivot

2026-01-25
U.S. stocks dip ahead of the Fed amid rate volatility, Davos headlines and REIT weakness; see what it means for investors and markets—read now.

Ventas Inc. stock outperforms competitors despite losses on the day

2026-01-22
Ventas Inc. stock outperforms competitors despite losses on the day

Ventas Stock Gains 10.9% in Three Months: Will it Continue to Rise?

2026-01-21
VTR shares are up 10.9% in three months, fueled by senior housing demand, outpatient trends, accretive investments and a stronger balance sheet.